Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1863127 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $33.06Day +6.27%Mkt cap $2.0B1Y +196.5%Off 52W high −18.7%Vol (1Y) 60.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,219 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest16.7% of sh out |
| Days to cover15.5d |
| 13F net flow (QoQ)+12.00% |
| Top-10 13F concentration68.4% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$131.1M |
| ROE−39.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+25.8% |
| 1Y+196.5% |
| 3Y+123.1% |
| Since incept. (ann.)+10.0% |
Total return through 2026-07-30 · series begins 2021-09-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)60.6% |
| Ann. volatility (3Y)64.0% |
| Sharpe (1Y)2.10 |
| Sharpe (3Y)0.74 |
| Max drawdown (1Y)−35.4% |
| Max drawdown (3Y)−75.3% |
| Beta (3Y vs SPY)0.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12.2M | $467M | — | +0.0% |
| FMR LLC | 7.7M | $297M | — | +61570.4% |
| Nextech Invest, Ltd. | 4.1M | $155M | — | +0.0% |
| JANUS HENDERSON GROUP PLC | 3.9M | $149M | — | +32.5% |
| Alta Partners Management Company, L.P. | 3.8M | $146M | — | +0.0% |
| FARALLON CAPITAL MANAGEMENT LLC | 3.6M | $137M | — | +73.3% |
| TCG Crossover Management, LLC | 3.2M | $124M | — | +12.1% |
| Commodore Capital LP | 2.5M | $95M | — | −26.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (66,208,898) exceed the cover-page shares-outstanding count for this quarter (53,867,115, as of 2026-02-25) by more than securities-lending double counting can explain (FINRA short interest 7,708,671 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.64 | — | — | — |
| 2025-09-30 | 2025-11-05 | −$0.50 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.47 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.47 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
